新诺威：关于控股子公司SYS6036注射液获得药物临床试验批准通知书的公告

Group 1 - The core point of the article is that XinNuoWei announced the approval of clinical trials for SYS6036 injection by the National Medical Products Administration [2] - The clinical trials will be conducted by the company's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. [2] - The announcement was made on the evening of August 22 [2] Group 2 - The approval signifies a step forward in the development of SYS6036, which may present potential investment opportunities in the biopharmaceutical sector [2] - The company is expected to initiate the clinical trials in the near future [2] - This development may enhance the company's product pipeline and market position [2]